The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kellner, M.
* Articles by Wiedemann, K.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Kellner, M.
* Articles by Wiedemann, K.
Related Collections
* Neuroendocrinology
* Posttraumatic Stress Disorder
Am J Psychiatry 159:1938-1940, November 2002
© 2002 American Psychiatric Association


Brief Report

Mineralocorticoid Receptor Function in Patients With Posttraumatic Stress Disorder

Michael Kellner, M.D., Dewleen G. Baker, M.D., Alexander Yassouridis, Ph.D., Silke Bettinger, Christian Otte, M.D., Dieter Naber, M.D., and Klaus Wiedemann, M.D.

OBJECTIVE: The study examined whether enhanced limbic mineralocorticoid receptor activity resulting in negative glucocorticoid feedback could contribute to the diminished basal and stress-induced cortisol output reported in patients with posttraumatic stress disorder (PTSD). METHOD: The effects of acute antimineralocorticoid (spironolactone) versus placebo pretreatment on levels of plasma cortisol at baseline and after stimulations with corticotropin-releasing hormone (CRH) and on adrenocorticotropic hormone (ACTH) level were measured in 12 PTSD patients and 12 healthy comparison subjects. RESULTS: Spironolactone significantly elevated basal cortisol and ACTH concentrations as well as cortisol secretion after CRH stimulation, but no differential effect between PTSD patients and comparison subjects was detected. CONCLUSIONS: The results indicate intact, but not enhanced, mineralocorticoid receptor function in PTSD. The study’s experimental conditions did not allow determination of whether other compensatory factors might have masked the putative mineralocorticoid receptor changes.




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
R. YEHUDA
Advances in Understanding Neuroendocrine Alterations in PTSD and Their Therapeutic Implications
Ann. N.Y. Acad. Sci., July 1, 2006; 1071(1): 137 - 166.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
T. C. NEYLAN, C. OTTE, R. YEHUDA, and C. R. MARMAR
Neuroendocrine Regulation of Sleep Disturbances in PTSD
Ann. N.Y. Acad. Sci., July 1, 2006; 1071(1): 203 - 215.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
C. Otte, A. Yassouridis, H. Jahn, P. Maass, N. Stober, K. Wiedemann, and M. Kellner
Mineralocorticoid Receptor-Mediated Inhibition of the Hypothalamic-Pituitary-Adrenal Axis in Aged Humans
J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2003; 58(10): B900 - 905.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org